Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal antibodies in patients with moderate-to-severe ulcerative colitis

Elisa K. Boden; James B. Canavan; Christopher J. Moran; Katelyn McCann; William A. Dunn; Francis A. Farraye; Ashwin N. Ananthakrishnan; Vijay Yajnik; Roopali Gandhi; Deanna D. Nguyen; Atul K. Bhan; Howard L. Weiner; Joshua R. Korzenik; Scott B. Snapper

doi:10.1093/crocol/otz009

Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal antibodies in patients with moderate-to-severe ulcerative colitis

Elisa K. Boden, James B. Canavan, Christopher J. Moran, Katelyn McCann, William A. Dunn, Francis A. Farraye, Ashwin N. Ananthakrishnan, Vijay Yajnik, Roopali Gandhi, Deanna D. Nguyen, Atul K. Bhan, Howard L. Weiner, Joshua R. Korzenik, Scott B. Snapper

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Aim: The aim of this study was to determine the immunologic effects and safety of oral anti-CD3 in patients with ulcerative colitis (UC). Methods: An open-label pilot study of orally delivered anti-CD3 was performed in patients with moderate-to-severe UC. The primary end points were changes in immunologic parameters and evaluation for safety. Results: Six subjects received oral OKT3. Biologic effects of oral anti-CD3 included significantly increased proliferation in response to anti-CD3 and anti-inflammatory gene expression profile in peripheral blood mononuclear cells. No serious treatment-related adverse events occurred. Conclusion: Orally delivered anti-CD3 resulted in immunologic changes in patients with UC.

Original language	English (US)
Journal	Crohn's and Colitis 360
Volume	1
Issue number	2
DOIs	https://doi.org/10.1093/crocol/otz009
State	Published - Jul 1 2019
Externally published	Yes

Keywords

Muromonab-CD3
Regulatory T cells
Ulcerative colitis

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1093/crocol/otz009

Cite this

Boden, E. K., Canavan, J. B., Moran, C. J., McCann, K., Dunn, W. A., Farraye, F. A., Ananthakrishnan, A. N., Yajnik, V., Gandhi, R., Nguyen, D. D., Bhan, A. K., Weiner, H. L., Korzenik, J. R., & Snapper, S. B. (2019). Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal antibodies in patients with moderate-to-severe ulcerative colitis. Crohn's and Colitis 360, 1(2). https://doi.org/10.1093/crocol/otz009

Boden, EK, Canavan, JB, Moran, CJ, McCann, K, Dunn, WA, Farraye, FA, Ananthakrishnan, AN, Yajnik, V, Gandhi, R, Nguyen, DD, Bhan, AK, Weiner, HL, Korzenik, JR & Snapper, SB 2019, 'Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal antibodies in patients with moderate-to-severe ulcerative colitis', Crohn's and Colitis 360, vol. 1, no. 2. https://doi.org/10.1093/crocol/otz009

@article{cc0ab3fe56224aadb453d96adce4149a,

title = "Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal antibodies in patients with moderate-to-severe ulcerative colitis",

abstract = "Aim: The aim of this study was to determine the immunologic effects and safety of oral anti-CD3 in patients with ulcerative colitis (UC). Methods: An open-label pilot study of orally delivered anti-CD3 was performed in patients with moderate-to-severe UC. The primary end points were changes in immunologic parameters and evaluation for safety. Results: Six subjects received oral OKT3. Biologic effects of oral anti-CD3 included significantly increased proliferation in response to anti-CD3 and anti-inflammatory gene expression profile in peripheral blood mononuclear cells. No serious treatment-related adverse events occurred. Conclusion: Orally delivered anti-CD3 resulted in immunologic changes in patients with UC.",

keywords = "Muromonab-CD3, Regulatory T cells, Ulcerative colitis",

author = "Boden, {Elisa K.} and Canavan, {James B.} and Moran, {Christopher J.} and Katelyn McCann and Dunn, {William A.} and Farraye, {Francis A.} and Ananthakrishnan, {Ashwin N.} and Vijay Yajnik and Roopali Gandhi and Nguyen, {Deanna D.} and Bhan, {Atul K.} and Weiner, {Howard L.} and Korzenik, {Joshua R.} and Snapper, {Scott B.}",

note = "Publisher Copyright: {\textcopyright} 2019 Crohn's & Colitis Foundation. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.",

year = "2019",

month = jul,

day = "1",

doi = "10.1093/crocol/otz009",

language = "English (US)",

volume = "1",

journal = "Crohn's and Colitis 360",

issn = "2631-827X",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal antibodies in patients with moderate-to-severe ulcerative colitis

AU - Boden, Elisa K.

AU - Canavan, James B.

AU - Moran, Christopher J.

AU - McCann, Katelyn

AU - Dunn, William A.

AU - Farraye, Francis A.

AU - Ananthakrishnan, Ashwin N.

AU - Yajnik, Vijay

AU - Gandhi, Roopali

AU - Nguyen, Deanna D.

AU - Bhan, Atul K.

AU - Weiner, Howard L.

AU - Korzenik, Joshua R.

AU - Snapper, Scott B.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Aim: The aim of this study was to determine the immunologic effects and safety of oral anti-CD3 in patients with ulcerative colitis (UC). Methods: An open-label pilot study of orally delivered anti-CD3 was performed in patients with moderate-to-severe UC. The primary end points were changes in immunologic parameters and evaluation for safety. Results: Six subjects received oral OKT3. Biologic effects of oral anti-CD3 included significantly increased proliferation in response to anti-CD3 and anti-inflammatory gene expression profile in peripheral blood mononuclear cells. No serious treatment-related adverse events occurred. Conclusion: Orally delivered anti-CD3 resulted in immunologic changes in patients with UC.

AB - Aim: The aim of this study was to determine the immunologic effects and safety of oral anti-CD3 in patients with ulcerative colitis (UC). Methods: An open-label pilot study of orally delivered anti-CD3 was performed in patients with moderate-to-severe UC. The primary end points were changes in immunologic parameters and evaluation for safety. Results: Six subjects received oral OKT3. Biologic effects of oral anti-CD3 included significantly increased proliferation in response to anti-CD3 and anti-inflammatory gene expression profile in peripheral blood mononuclear cells. No serious treatment-related adverse events occurred. Conclusion: Orally delivered anti-CD3 resulted in immunologic changes in patients with UC.

KW - Muromonab-CD3

KW - Regulatory T cells

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85086181881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086181881&partnerID=8YFLogxK

U2 - 10.1093/crocol/otz009

DO - 10.1093/crocol/otz009

M3 - Article

AN - SCOPUS:85086181881

SN - 2631-827X

VL - 1

JO - Crohn's and Colitis 360

JF - Crohn's and Colitis 360

IS - 2

ER -

Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal antibodies in patients with moderate-to-severe ulcerative colitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this